CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02171 CARSGEN-B

Not Yet Opened 08-26 16:08:03

13.360

+0.000

0.00%

High13.980	Low13.310	Vol2.59M
Open13.640	D1 Closing13.360	Amplitude5.02%
Mkt Cap7.94B	Tradable Cap7.94B	Total Shares594.00M
T/O35.00M	T/O Rate0.44%	Tradable Shares594.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"CARSGEN-B","latestPrice":13.36,"timestamp":1787731683004,"preClose":13.36,"halted":0,"volume":2589500,"delay":0,"changeRate":0,"floatShares":594000000,"shares":594000000,"eps":-0.177264,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-26 16:08:03","open":13.64,"high":13.98,"low":13.31,"amount":35000442,"amplitude":0.05015,"askPrice":13.46,"askSize":4000,"bidPrice":13.36,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.173,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":0,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":13.36,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"volumeRatio":0.6594763917775777,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2660431424","title":"CARsgen Therapeutics (SEHK:2171) Stock Carries Premium Valuation Despite Ongoing Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431424","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431424?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:27","pubTimestamp":1787142431,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings closed at HK$14.90 today after a choppy few months in which the stock has slipped about 15% over 90 days. Yet behind the weak chart, the latest half year numbers point to one issue that matters most for you as a shareholder. The balance sheet and valuation strain is now the key tension between short term sentiment and long term promise.\nRevenue for the first half of 2026 came in at ¥61.9 million, while the company still reported a net loss of ¥66.7 million. With...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-sehk2171-stock-carries-premium-valuatio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-sehk2171-stock-carries-premium-valuatio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1585","BK4139","BK4007","BK1574","02171","BK1587","LENZ","BK1161","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155552295","title":"CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1155552295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155552295?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:20","pubTimestamp":1787106032,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its shares rally nearly 5% in Thursday morning trade following the release of its interim results. The stock was up 4.63% at HK$15.38 at the time of writing, with turnover...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","02171","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241822","title":"Press Release: CARsgen Therapeutics Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241822?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:15","pubTimestamp":1787098500,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results.Business Highlights-- Cash and cash equivalents were around RMB1,400 million as of June 30,2026. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,200 million. In light of operational factors, we expect to. -- During H1, 2026, CARsgen has received a total of 110 confirmed orders of. -- Satri-cel receives NMPA approval in June 2026 as world's first and only. CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L. treatment in patients with G/GEJA have been presented at the 2026 ASCO. -- Multiple allogeneic CAR T-cell products are under development based on. the proprietary THANK--u Plus platform. Among them, research results. for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in. the treatment of R/R B--NHL, have been presented at the E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4560","03160","LU2506952097.USD","BK1574","BK4022","IE00B1BXHZ80.USD","LU2417539215.USD","LU0070302665.USD","LU2237443465.HKD","BK0187","CAR","LU1221951129.SGD","LU2328871848.SGD","LU1046421795.USD","TM","BK4515","PC","LU0868494617.USD","CSCS","LU0942090050.USD","CIBR","CSCO","LU1032955483.USD","02171","LU2462157665.USD","LU0203345920.USD","BK1587","R","IYZ","LU1599440770.SGD","LU1929549753.HKD","BK4230","IE00BVYPNV92.GBP","LU1430594728.SGD","LU0950375773.USD","BK0209","BK4612","SG9999001424.SGD","BK4533","LU0823417653.USD","000963","BK4534","IE00B3PB1722.GBP","CSCL","LU1674673428.USD","AIQ","SG9999001440.SGD","LENZ","LU2237443622.USD","IE00B42XCP33.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494978","title":"CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494978?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:24","pubTimestamp":1787077458,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02171","BK4139","BK1574","IND","BK1587","BK4007","BK1161","BK1585","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142295338","title":"CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing","url":"https://stock-news.laohu8.com/highlight/detail?id=1142295338","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142295338?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:46","pubTimestamp":1787064361,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics (CARSGEN-B, 02171) released its unaudited results for the six months ended 30 June 2026. Financial highlights   • Revenue rose 21.5% year-on-year to RMB61.92 million, driven by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182420401","title":"CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners","url":"https://stock-news.laohu8.com/highlight/detail?id=1182420401","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182420401?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:38","pubTimestamp":1787063895,"startTime":"0","endTime":"0","summary":"CARsgen-B (02171) has released its interim results for 2026, reporting revenue of approximately RMB 61.919 million, a year-on-year increase of 21.5%. The adjusted net loss came in at RMB 31.927...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1585","BK1587","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544493","title":"CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660544493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:28","pubTimestamp":1787063306,"startTime":"0","endTime":"0","summary":"CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionCARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales vol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbGD37X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK0175","BK0187","BK0132","BK1587","LU1969619763.USD","02171","BK1574","000963","BK0196","BK1161","BK0183","LU2328871848.SGD","BK0188","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657226618","title":"CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2657226618","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657226618?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:38","pubTimestamp":1786088298,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  said its investigational new drug application for CT1190B, an allogeneic CAR T-cell therapy targeting CD19/CD20, received clearance from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The clearance allows the company to begin a clinical trial of CT1190B in patients with relapsed or refractory large B-cell lymphoma who have failed at least two prior lines of standard therapy.z","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1585","02171","BK4539","BK4139","LENZ","IND","BK1587","BK1161","BK4007","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163799508","title":"CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1163799508","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163799508?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:52","pubTimestamp":1786071162,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","02171","BK1587","BK1161","BK4585","VXUS","KCAI","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147606546","title":"CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1147606546","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147606546?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:12","pubTimestamp":1786061532,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).This \"off-the-shelf\"...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","IND","BK1587","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657132664","title":"CARsgen Says NMPA Clears IND for Ct1190b in Relapsed/refractory Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657132664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657132664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:00","pubTimestamp":1786060851,"startTime":"0","endTime":"0","summary":"CARsgen says NMPA clears IND for CT1190B in relapsed/refractory large B-cell lymphomaCARsgen won NMPA IND clearance for CT1190B in relapsed or refractory large B-cell lymphoma patients who failed at l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1G2L5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1585","BK1161","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666418","title":"CARsgen Therapeutics - Ct1190b Receives Ind Clearance from Nmpa for Relapsed/Refractory Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666418?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:00","pubTimestamp":1786060840,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4432H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","BK1161","BK1587","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134654610","title":"CARsgen Schedules 18 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1134654610","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134654610?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:46","pubTimestamp":1786009584,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited announced that its board of directors will convene on 18 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026, and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681531","title":"CARsgen Therapeutics Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657681531?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:31","pubTimestamp":1786008676,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics schedules board meeting to review interim resultsCARsgen Therapeutics will hold a board meeting on Aug. 18, 2026 to review the group’s interim results for the six months ended Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL73lfnB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1587","BK1161","BK1585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958065","title":"CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958065?lang=en_us&edition=fundamental","pubTime":"2026-08-04 14:30","pubTimestamp":1785825028,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics' (HKG:2171) CT0596 obtained investigational new drug clearance from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02171","BK4139","BK1574","IND","BK1587","BK4007","BK1161","BK1585","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656586682","title":"Carsgen Therapeutics Says Ct0596 Receives IND Clearance from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2656586682","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656586682?lang=en_us&edition=fundamental","pubTime":"2026-08-04 09:52","pubTimestamp":1785808348,"startTime":"0","endTime":"0","summary":"BRIEF-Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPAAug 4 (Reuters)-CARsgen Therapeutics Holdings Ltd2171.HK:CT0596 RECEIVES IND CLEARANCE FROM NMPA FOR RELAPSED/REFRACTORY MULTIPLE MYELOMAFurther company coverage:2171.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44012P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","BK1587","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151736677","title":"China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=1151736677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151736677?lang=en_us&edition=fundamental","pubTime":"2026-08-04 08:14","pubTimestamp":1785802452,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1574","IND","BK1587","BK1585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136831406","title":"CARsgen Secures NMPA IND Clearance for Allogeneic BCMA CAR-T Candidate CT0596 in Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=1136831406","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136831406?lang=en_us&edition=fundamental","pubTime":"2026-08-04 08:03","pubTimestamp":1785801835,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Limited (CARsgen) announced that the National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) clearance for CT0596, an allogeneic...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588436","title":"CARsgen Says Ct0596 Wins NMPA IND Clearance for Relapsed/refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588436?lang=en_us&edition=fundamental","pubTime":"2026-08-04 08:01","pubTimestamp":1785801704,"startTime":"0","endTime":"0","summary":"CARsgen says CT0596 wins NMPA IND clearance for relapsed/refractory multiple myelomaCARsgen won NMPA IND clearance for CT0596, an allogeneic BCMA-targeted CAR-T, in relapsed or refractory multiple mye","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7mlDDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1585","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656881035","title":"CARsgen Therapeutics - Ct0596 Receives Ind Clearance from Nmpa for Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2656881035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656881035?lang=en_us&edition=fundamental","pubTime":"2026-08-04 08:00","pubTimestamp":1785801657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44012P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","02171","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.1034},{"period":"1month","weight":-0.0572},{"period":"3month","weight":-0.2146},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.4046},{"period":"ytd","weight":-0.1003}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0259},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.022715},{"month":8,"riseRate":0.5,"avgChangeRate":0.054543},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"CARSGEN-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CARSGEN-B,02171,CARSGEN-B股票,CARSGEN-B股票老虎,CARSGEN-B股票老虎国际,CARSGEN-B行情,CARSGEN-B股票行情,CARSGEN-B股价,CARSGEN-B股市,CARSGEN-B股票价格,CARSGEN-B股票交易,CARSGEN-B股票购买,CARSGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}